成都先導(dǎo)藥物開(kāi)發(fā)股份有限公司（上海證券交易所股票代碼：688222.SH，股票名稱(chēng)：成都先導(dǎo)）致力于打造全球一流的創(chuàng)新型生物醫(yī)藥企業(yè)，總部位于中國(guó)成都，在英國(guó)劍橋、美國(guó)休斯頓設(shè)有子公司。公司聚焦小分子及核酸新藥的發(fā)現(xiàn)與優(yōu)化，著力打造了DNA編碼化合物庫(kù)技術(shù)（包括DEL庫(kù)的設(shè)計(jì)、合成和篩選及拓展應(yīng)用）、基于分子片段和三維結(jié)構(gòu)信息的藥物設(shè)計(jì)技術(shù)（FBDD/SBDD）、寡聚核酸新藥研發(fā)平臺(tái)相關(guān)技術(shù)（STO）、靶向蛋白降解平臺(tái)相關(guān)技術(shù)（TPD）等四個(gè)核心技術(shù)平臺(tái)。通過(guò)新藥研發(fā)服務(wù)、不同階段在研項(xiàng)目轉(zhuǎn)讓以及遠(yuǎn)期的藥物上市等多元化的商業(yè)模式，成都先導(dǎo)與全球數(shù)百家制藥公司、生物技術(shù)公司、化學(xué)公司、基金會(huì)以及科研機(jī)構(gòu)建立了合作。目前，公司有多個(gè)內(nèi)部新藥項(xiàng)目處于臨床及臨床前不同階段。
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.